Allergy, Asthma & Clinical Immunology

CORRECTION

Open Access

# Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study

Paul K. Keith[1], Juthaporn Cowan[2], Amin Kanani[3], Harold Kim[1,4], Gina Lacuesta[5], Jason K. Lee[6], Jie Chen[7], Michelle Park[7] and André Gladiator[8*]

**Correction: Allergy, Asthma & Clinical Immunology (2022) 18:70**
**https://doi.org/10.1186/s13223-022-00709-8**

Following the publication of our article [1], a previously undetected error in the data set has come to our attention. MedDRA-coded preferred terms (PTs) were not coded in the derived adverse event (AE) data set used for the summary of AEs and AEs of interest. While the overall number of AEs was reported correctly in the published article, three AEs that were originally categorized as 'other' have now been re-categorized. Consequently, safety data presented in the Results require correction.

Firstly, in the *Safety* subsection, the first sentence stated: "In total, 20 AEs of interest (in 15 patients) and 29 other AEs (in 20 patients) were reported (Table 3)."

It should instead read: "In total, 23 AEs of interest (in 16 patients) and 26 other AEs (in 19 patients) were reported (Table 3)."

The original article can be found online at https://doi.org/10.1186/s13223-022-00709-8.

*Correspondence:
André Gladiator
andre.gladiator@takeda.com
[1] Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada
[2] Division of Infectious Diseases, Department of Medicine, Department of Biochemistry, Microbiology, and Immunology; Centre for Infection, Immunity and Inflammation, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON K1H 8M5, Canada
[3] Division of Allergy and Clinical Immunology, Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada
[4] Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, ON N6A 5A5, Canada
[5] Department of Medicine, Dalhousie University, Halifax, NS B3H 2Y9, Canada
[6] Chair of Toronto Allergists and Evidence Based Medical Educator, Toronto, ON M5G 1E2, Canada
[7] Takeda Development Center Americas, Inc., Cambridge, MA 02139, USA
[8] Glattpark-Opfikon, Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, 8152 Zurich, Switzerland

© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

The referenced *Table 3 (Summary of AEs)* originally presented the following data:

| | AEs of interest | | Other AEs | | SAEs[a] | |
|---|---|---|---|---|---|---|
| | Patients, n (%) (N = 125) | AEs, n | Patients, n (%) (N = 125) | AEs, n | Patients, n (%) (N = 125) | AEs, n |
| Any AE | 15 (12.0) | 20 | 20 (16.0) | 29 | 5 (4.0) | 5 |
| Severity of AE[b] | | | | | | |
| Mild | 10 (8.0) | 13 | 11 (8.8) | 14 | 0 | 0 |
| Moderate | 5 (4.0) | 6 | 6 (4.8) | 12 | 1 (0.8) | 1 |
| Severe | 1 (0.8) | 1 | 3 (2.4) | 3 | 4 (3.2) | 4 |
| AEs considered related to Ig20Gly | | | | | | |
| Related | 7 (5.6) | 8 | 3 (2.4) | 4 | 0 | 0 |
| Possibly related | 5 (4.0) | 5 | 4 (3.2) | 6 | 1 (0.8) | 1 |
| Probably related | 2 (1.6) | 2 | 2 (1.6) | 2 | 0 | 0 |

*Table 3* should instead present the following corrected data:

| | AEs of interest | | Other AEs | | SAEs[a] | |
|---|---|---|---|---|---|---|
| | Patients, n (%) (N = 125) | AEs, n | Patients, n (%) (N = 125) | AEs, n | Patients, n (%) (N = 125) | AEs, n |
| Any AE | 16 (12.8) | 23 | 19 (15.2) | 26 | 5 (4.0) | 5 |
| Severity of AE[b] | | | | | | |
| Mild | 11 (8.8) | 14 | 10 (8.0) | 13 | 0 | 0 |
| Moderate | 5 (4.0) | 8 | 6 (4.8) | 10 | 1 (0.8) | 1 |
| Severe | 1 (0.8) | 1 | 3 (2.4) | 3 | 4 (3.2) | 4 |
| AEs considered related to Ig20Gly | | | | | | |
| Related | 7 (5.6) | 8 | 3 (2.4) | 4 | 0 | 0 |
| Possibly related | 5 (4.0) | 7 | 4 (3.2) | 4 | 1 (0.8) | 1 |
| Probably related | 2 (1.6) | 2 | 2 (1.6) | 2 | 0 | 0 |

Safety data in *Additional file 2: Table S1 (AEs of interest)*, referenced in the *Safety* subsection, were originally presented as follows:

| AE of interest | Patients, n (%) (N = 125) | |
|---|---|---|
| | All causality | Considered related to Ig20Gly |
| Nausea | 2 (1.6) | 1 (0.8) |
| Diarrhea | 1 (0.8) | 0 |
| Headache | 6 (4.8) | 3 (2.4) |
| Cough | 2 (1.6) | 0 |
| Stroke | 1 (0.8) | 0 |
| Fatigue | 2 (1.6) | 0 |
| Infusion-site erythema (redness) | 1 (0.8) | 1 (0.8) |
| Infusion-site pain | 3 (2.4) | 3 (2.4) |
| Infusion-site pruritus (itchiness) | 1 (0.8) | 0 |

*Table S1* should instead present the following corrected data for all causality fatigue:

| AE of interest | Patients, n (%) (N = 125) | |
|---|---|---|
| | All causality | Considered related to Ig20Gly |
| Nausea | 2 (1.6) | 1 (0.8) |
| Diarrhea | 1 (0.8) | 0 |
| Headache | 6 (4.8) | 3 (2.4) |
| Cough | 2 (1.6) | 0 |
| Stroke | 1 (0.8) | 0 |
| Fatigue | 3 (2.4) | 0 |
| Infusion-site erythema (redness) | 1 (0.8) | 1 (0.8) |
| Infusion-site pain | 3 (2.4) | 3 (2.4) |
| Infusion-site pruritus (itchiness) | 1 (0.8) | 0 |

Safety data in *Additional file 2: Table S4 (AEs by mode of Ig20Gly administration)*, referenced in the *Subgroup analysis by mode of administration at 12 months* subsection, were originally presented as follows:

| | AEs of interest | | | | Other AEs | | | | SAEs | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Infusion pump | | Manual | | Infusion pump | | Manual | | Infusion pump | | Manual | |
| | Patients, n (%) (N = 71) | AEs, n | Patients, n (%) (N = 54) | AEs, n | Patients, n (%) (N = 71) | AEs, n | Patients, n (%) (N = 54) | AEs, n | Patients, n (%) (N = 71) | AEs, n | Patients, n (%) (N = 54) | AEs, n |
| Any AE | 6 (8.5) | 9 | 9 (16.7) | 11 | 12 (16.9) | 13 | 8 (14.8) | 16 | 5 (7.0) | 5 | 0 | 0 |
| Severity of AE | | | | | | | | | | | | |
| Mild | 4 (5.6) | 7 | 6 (11.1) | 6 | 6 (8.5) | 7 | 5 (9.3) | 7 | 0 | 0 | 0 | 0 |
| Moderate | 1 (1.4) | 1 | 4 (7.4) | 5 | 3 (4.2) | 3 | 3 (5.6) | 9 | 1 (1.4) | 1 | 0 | 0 |
| Severe | 1 (1.4) | 1 | 0 | 0 | 3 (4.2) | 3 | 0 | 0 | 4 (5.6) | 4 | 0 | 0 |
| AEs considered related to Ig20Gly | | | | | | | | | | | | |
| Related | 3 (4.2) | 3 | 4 (7.4) | 5 | 2 (2.8) | 3 | 1 (1.9) | 1 | 0 | 0 | 0 | 0 |
| Possibly related | 2 (2.8) | 2 | 3 (5.6) | 3 | 2 (2.8) | 2 | 2 (3.7) | 4 | 1 (1.4) | 1 | 0 | 0 |
| Probably related | 1 (1.4) | 1 | 1 (1.9) | 1 | 0 | 0 | 2 (3.7) | 2 | 0 | 0 | 0 | 0 |

*Table S4* should instead present the following corrected data for the manual administration subgroup:

| | AEs of interest | | | | Other AEs | | | | SAEs | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Infusion pump | | Manual | | Infusion pump | | Manual | | Infusion pump | | Manual | |
| | Patients, n (%) (N = 71) | AEs, n | Patients, n (%) (N = 54) | AEs, n | Patients, n (%) (N = 71) | AEs, n | Patients, n (%) (N = 54) | AEs, n | Patients, n (%) (N = 71) | AEs, n | Patients, n (%) (N = 54) | AEs, n |
| Any AE | 6 (8.5) | 9 | 10 (18.5) | 14 | 12 (16.9) | 13 | 7 (13.0) | 13 | 5 (7.0) | 5 | 0 | 0 |
| Severity of AE | | | | | | | | | | | | |
| Mild | 4 (5.6) | 7 | 7 (13.0) | 7 | 6 (8.5) | 7 | 4 (7.4) | 6 | 0 | 0 | 0 | 0 |
| Moderate | 1 (1.4) | 1 | 4 (7.4) | 7 | 3 (4.2) | 3 | 3 (5.6) | 7 | 1 (1.4) | 1 | 0 | 0 |
| Severe | 1 (1.4) | 1 | 0 | 0 | 3 (4.2) | 3 | 0 | 0 | 4 (5.6) | 4 | 0 | 0 |
| AEs considered related to Ig20Gly | | | | | | | | | | | | |
| Related | 3 (4.2) | 3 | 4 (7.4) | 5 | 2 (2.8) | 3 | 1 (1.9) | 1 | 0 | 0 | 0 | 0 |
| Possibly related | 2 (2.8) | 2 | 3 (5.6) | 5 | 2 (2.8) | 2 | 2 (3.7) | 2 | 1 (1.4) | 1 | 0 | 0 |
| Probably related | 1 (1.4) | 1 | 1 (1.9) | 1 | 0 | 0 | 2 (3.7) | 2 | 0 | 0 | 0 | 0 |

Finally, safety data in *Additional file 2: Table S6 (AEs by indication)*, referenced in the *Subgroup analysis by indication at 12 months* subsection, were originally presented as follows:

| Parameter, n (%) | AEs of interest | | | | Other AEs | | | | SAEs | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | PID | | SID | | PID | | SID | | PID | | SID | |
| | Patients, n (%) (N = 61) | AEs, n | Patients, n (%) (N = 64) | AEs, n | Patients, n (%) (N = 61) | AEs, n | Patients, n (%) (N = 64) | AEs, n | Patients, n (%) (N = 61) | AEs, n | Patients, n (%) (N = 64) | AEs, n |
| Any AE | 10 (16.4) | 15 | 5 (7.8) | 5 | 8 (13.1) | 14 | 12 (18.8) | 15 | 1 (1.6) | 1 | 4 (6.3) | 4 |
| Severity of AE | | | | | | | | | | | | |
| Mild | 7 (11.5) | 10 | 3 (4.7) | 3 | 6 (9.8) | 8 | 5 (7.8) | 6 | 0 | 0 | 0 | 0 |
| Moderate | 3 (4.9) | 4 | 2 (3.1) | 2 | 2 (3.3) | 6 | 4 (6.3) | 6 | 0 | 0 | 1 (1.6) | 1 |
| Severe | 1 (1.6) | 1 | 0 | 0 | 0 | 0 | 3 (4.7) | 3 | 1 (1.6) | 1 | 3 (4.7) | 3 |

| Parameter, n (%) | AEs of interest | | | | Other AEs | | | | SAEs | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | PID | | SID | | PID | | SID | | PID | | SID | |
| | Patients, n (%) (N = 61) | AEs, n | Patients, n (%) (N = 64) | AEs, n | Patients, n (%) (N = 61) | AEs, n | Patients, n (%) (N = 64) | AEs, n | Patients, n (%) (N = 61) | AEs, n | Patients, n (%) (N = 64) | AEs, n |
| AEs considered related to Ig20Gly | | | | | | | | | | | | |
| Related | 5 (8.2) | 6 | 2 (3.1) | 2 | 2 (3.3) | 2 | 1 (1.6) | 2 | 0 | 0 | 0 | 0 |
| Possibly related | 3 (4.9) | 3 | 2 (3.1) | 2 | 2 (3.3) | 2 | 2 (3.1) | 4 | 1 (1.6) | 1 | 0 | 0 |
| Probably related | 1 (1.6) | 1 | 1 (1.6) | 1 | 1 (1.6) | 1 | 1 (1.6) | 1 | 0 | 0 | 0 | 0 |

*Table S6* should instead present the following corrected data:

| Parameter, n (%) | AEs of interest | | | | Other AEs | | | | SAEs | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | PID | | SID | | PID | | SID | | PID | | SID | |
| | Patients, n (%) (N = 61) | AEs, n | Patients, n (%) (N = 64) | AEs, n | Patients, n (%) (N = 61) | AEs, n | Patients, n (%) (N = 64) | AEs, n | Patients, n (%) (N = 61) | AEs, n | Patients, n (%) (N = 64) | AEs, n |
| Any AE | 11 (18.0) | 16 | 5 (7.8) | 7 | 7 (11.5) | 13 | 12 (18.8) | 13 | 1 (1.6) | 1 | 4 (6.3) | 4 |
| Severity of AE | | | | | | | | | | | | |
| Mild | 8 (13.1) | 11 | 3 (4.7) | 3 | 5 (8.2) | 7 | 5 (7.8) | 6 | 0 | 0 | 0 | 0 |
| Moderate | 3 (4.9) | 4 | 2 (3.1) | 4 | 2 (3.3) | 6 | 4 (6.3) | 4 | 0 | 0 | 1 (1.6) | 1 |
| Severe | 1 (1.6) | 1 | 0 | 0 | 0 | 0 | 3 (4.7) | 3 | 1 (1.6) | 1 | 3 (4.7) | 3 |
| AEs considered related to Ig20Gly | | | | | | | | | | | | |
| Related | 5 (8.2) | 6 | 2 (3.1) | 2 | 2 (3.3) | 2 | 1 (1.6) | 2 | 0 | 0 | 0 | 0 |
| Possibly related | 3 (4.9) | 3 | 2 (3.1) | 4 | 2 (3.3) | 2 | 2 (3.1) | 2 | 1 (1.6) | 1 | 0 | 0 |
| Probably related | 1 (1.6) | 1 | 1 (1.6) | 1 | 1 (1.6) | 1 | 1 (1.6) | 1 | 0 | 0 | 0 | 0 |

Please note that the conclusions made in the original publication are unaffected by the errors identified.

Accepted: 24 May 2023
Published online: 23 June 2023

**Reference**

1. Keith PK, Cowan J, Kanani A, Kim H, Lacuesta G, Lee JK, Chen J, Park M, Gladiator A. Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study. Allergy Asthma Clin Immunol. 2022;18:70. https://doi.org/10.1186/s13223-022-00709-8.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

**Learn more** biomedcentral.com/submissions

BMC